Hematologic parameters of patients at enrollment and after rituximab treatment
| . | Enrollment (n = 14) . | Month 2 (n = 14) . | Month 6 (n = 14) . | Month 12 (n = 14) . |
|---|---|---|---|---|
| WAIHA, median (range) | ||||
| Hb, g/dL | 8.7 (4.4-13.2) | 13.1 (11.2-15.3) | 13.5 (10.4-17.1) | 13.3 (10.6-15.4) |
| Reticulocyte, × 109/L | 205 (40-320) | 90 (30-274) | 76 (40-250) | 83 (45-160) |
| LDH, U/L | 623 (314-1961) | 479 (341-1031) | 417 (276-605) | 403 (281-816) |
| Unconjugated bilirubin, mg/dL | 1.66 (0.4-6.4) | 0.5 (0.2-2.1) | 0.6 (0.2-1.3) | 0.63 (0.2-1.4) |
| CHD, median (range) | (n = 9) | (n = 9) | (n = 8) | (n = 4) |
| Hb, g/dL | 9.4 (7.1-12.2) | 9.8 (9.1-14.9) | 11.7 (9.2-14.5) | 11.6 (11.1-12.6) |
| Reticulocyte, × 109/L | 140 (52-269) | 101 (40-210) | 95 (72-130) | 90 (36-148) |
| LDH, U/L | 629 (420-2173) | 547 (257-1367) | 457 (273-718) | 414 (318-464) |
| Unconjugated bilirubin, mg/dL | 1.66 (0.6-3.6) | 1.34 (0.4-2.7) | 0.8 (0.7-1.3) | 0.7 (0.5-0.8) |
| . | Enrollment (n = 14) . | Month 2 (n = 14) . | Month 6 (n = 14) . | Month 12 (n = 14) . |
|---|---|---|---|---|
| WAIHA, median (range) | ||||
| Hb, g/dL | 8.7 (4.4-13.2) | 13.1 (11.2-15.3) | 13.5 (10.4-17.1) | 13.3 (10.6-15.4) |
| Reticulocyte, × 109/L | 205 (40-320) | 90 (30-274) | 76 (40-250) | 83 (45-160) |
| LDH, U/L | 623 (314-1961) | 479 (341-1031) | 417 (276-605) | 403 (281-816) |
| Unconjugated bilirubin, mg/dL | 1.66 (0.4-6.4) | 0.5 (0.2-2.1) | 0.6 (0.2-1.3) | 0.63 (0.2-1.4) |
| CHD, median (range) | (n = 9) | (n = 9) | (n = 8) | (n = 4) |
| Hb, g/dL | 9.4 (7.1-12.2) | 9.8 (9.1-14.9) | 11.7 (9.2-14.5) | 11.6 (11.1-12.6) |
| Reticulocyte, × 109/L | 140 (52-269) | 101 (40-210) | 95 (72-130) | 90 (36-148) |
| LDH, U/L | 629 (420-2173) | 547 (257-1367) | 457 (273-718) | 414 (318-464) |
| Unconjugated bilirubin, mg/dL | 1.66 (0.6-3.6) | 1.34 (0.4-2.7) | 0.8 (0.7-1.3) | 0.7 (0.5-0.8) |
Normal ranges: Hb, 13.6-16.7 g/dL; reticulocytes, 16-84 × 109/L; lactate dehydrogenase (LDH), 240-480 U/L; unconjugated bilirubin, < 0.75 mg/dL. CHD values at month +6 are shown for 8 cases (excluding 1 relapsed at month +4) and at month +12 for 4 cases (excluding 2 further relapses, 1 of whom has not yet reached the follow-up, and 1 who died at month +7).